Tab Application Banner
  • Users Online: 101
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2020  |  Volume : 15  |  Issue : 5  |  Page : 64-70

Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!


1 Department of Rheumatology, Hospital Universitario Torrecárdenas, Almería, Spain
2 Department of Rheumatology, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust; Department of Research, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England; Department of Research, Torrecárdenas University Hospital, Bellvitge University Hospital-IDIBELL, Barcelona, Spain
3 Department of Rheumatology, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust; Department of Research, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England

Correspondence Address:
Dr. Concepcion Castillo-Gallego
Hospital Universitario Torrecardenas, Almeria
Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-3698.284744

Rights and Permissions

The management of axial spondyloarthritis (axSpA) has been completely transformed since the introduction of biologic therapies. Tumor necrosis factor inhibitors (TNFis) were the first effective drug therapies in people affected with axSpA who had previously failed to respond to nonsteroidal anti-inflammatory drugs. Currently, there are five TNFis licensed for the treatment of established axSpA, traditionally known as ankylosing spondylitis or radiographic axSpA, with four of them also available for use in the nonradiographic axSpA disease group. More recent developments comprise new drugs designed to block the interleukin-17 or JAK inflammatory pathways. The high cost associated to these drugs has been the main limiting factor for their use and availability at global level, a problem that will, in part, be addressed with the recent introduction of biosimilars, with comparable efficacy and safety profile at lower cost. The fast arrival of so many “kids on the block” poses many challenges for the clinician in order to choose the right drug for each patient and brings the need for feasible, well-validated biomarkers of treatment response to the forefront of research in axSpA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed82    
    Printed0    
    Emailed0    
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal